SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED

PURSUANT TO RULES 13d-1 (b) (c), AND (d) AND AMENDMENTS

THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No. 3)*

Poniard Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, $0.02 par value per share

(Title of Class of Securities)

732449301

(CUSIP Number)

December 31, 2008

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

x Rule 13d-1(c)

¨ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SEC 1745 (3-98)

1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)             Abingworth Management Limited
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)  ¨ (b)  ¨
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION             England

NUMBER OF   SHARES   BENEFICIALLY   OWNED BY   EACH   REPORTING   PERSON   WITH:	5    SOLE VOTING POWER             2,331,286
	6    SHARED VOTING POWER             0
	7    SOLE DISPOSITIVE POWER             2,331,286
	8    SHARED DISPOSITIVE POWER             0

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON             2,331,286
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9             6.7%
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)             CO

1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)             Abingworth LLP
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)  ¨ (b)  ¨
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION             England

NUMBER OF   SHARES   BENEFICIALLY   OWNED BY   EACH   REPORTING   PERSON   WITH:	5    SOLE VOTING POWER             0
	6    SHARED VOTING POWER             2,331,286
	7    SOLE DISPOSITIVE POWER             0
	8    SHARED DISPOSITIVE POWER             2,331,286

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON             2,331,286
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9             6.7%
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)             PN

Item 1	(a).	Name of Issuer:
		Poniard Pharmaceuticals, Inc., formerly NeoRx Corporation (the “Issuer”)
Item 1	(b).	Address of Issuer’s Principal Executive Offices:
		7000 Shoreline Court, Suite 270 South San Francisco, CA 94080
Item 2	(a).	Name of Persons Filing:
		Abingworth Management and Abingworth LLP. The foregoing individuals are each a “Reporting Person” and collectively referred to as the “Reporting Persons.”
Item 2	(b).	Address of Principal Business Office or, if None, Residence:
		The business address for each Reporting Person is Princes House, 38 Jermyn Street, London, England SW1Y 6DN.
Item 2	(c).	Citizenship:
		Abingworth Management is a corporation organized under the laws of England. Abingworth LLP is a limited liability partnership organized under the laws of England.
Item 2	(d).	Title of Class of Securities:
		Common Stock, $0.02 par value per share (the “Common Stock”)
Item 2	(e).	CUSIP Number:
		732449301
Item 3.	If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person filing is a:
	Not applicable.

Item 4.	Ownership.
	(a)	Amount Beneficially Owned:
		Abingworth Management is the manager of Abingworth Bioventures IV LP (“ABV IV”) and Abingworth Bioventures IV Executives LP (“ABV IV Execs”). As of December 31, 2008, ABV IV is the record owner of 576,297 shares of Common Stock; and ABV IV Execs is the record owner of 4,942 shares of Common Stock. In addition, ABV IV is the record owner of warrants which are immediately exercisable for 159,348 shares of Common Stock and ABV IV Execs is the record owner of warrants which are immediately exercisable for 1,366 shares of Common Stock. As the manager of ABV IV and ABV IV Execs, Abingworth Management may be deemed to beneficially own the shares of Common Stock and warrants exercisable for shares of Common Stock held by ABV IV and ABV IV Execs. Abingworth LLP is the manager of Abingworth Bioventures V LP (“ABV V”) and Abingworth Bioequities Master Fund LTD (“ABE”). As of December 31, 2008, ABV V is the record owner of 737,501 shares of Common Stock and ABE is the record owner of 655,404 shares of Common Stock. In addition, ABE is the record owner of warrants which are immediately exercisable for 196,428 shares of Common Stock. As the manager of ABV V and ABE, Abingworth LLP may be deemed to beneficially own the shares of Common Stock and warrants exercisable for shares of Common Stock held by ABV V and ABE. As investment decisions for the investment funds managed by Abingworth Management (ABV IV and ABV IV Execs) and Abingworth LLP (ABV V and ABE) are made by investment committees comprised of substantially the same individuals, each of Abingworth Management and Abingworth LLP may be deemed to beneficially own 2,331,286 shares of Common Stock, which represents the shares of Common Stock and warrants exercisable for shares of Common Stock held by ABV IV, ABV IV Execs, ABV V and ABE.
	(b)	Percent of Class:
		Abingworth Management and Abingworth LLP may each be deemed to beneficially own 6.7% of the outstanding Common Stock of the Issuer. The foregoing percentage is calculated based on the 34,687,724 shares of Common Stock reported to be outstanding as of October 31, 2008 as reported in the Issuer’s Form 10-Q filed with the Securities Exchange Commission on November 6, 2008.
	(c)	Number of shares as to which such person has:
		(i)	sole power to vote or to direct the vote:
			see line 5 of cover sheet.
		(ii)	shared power to vote or to direct the vote:
			see line 6 of cover sheet.
		(iii)	sole power to dispose or to direct the disposition:
			see line 7 of cover sheet.
		(iv)	shared power to dispose or to direct the disposition:
			see line 8 of cover sheet.
	Each Reporting Person disclaims beneficial ownership of such shares of Common Stock except for the shares, if any, such Reporting Person holds of record.
Item 5.	Ownership of Five Percent or Less of a Class.
	Not applicable.
Item 6.	Ownership of More than Five Percent on Behalf of Another Person.
	Not applicable.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not applicable.
Item 8.	Identification and Classification of Members of the Group.
	Not applicable.
Item 9.	Notice of Dissolution of Group.
	Not applicable.
Item 10.	Certification.
	By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date:	February 13, 2009
ABINGWORTH MANAGEMENT LIMITED
By:	/s/ James Abell
Name:	James Abell
Title:	Executive Director
ABINGWORTH LLP
By:	/s/ James Abell
Name:	James Abell
Title:	Member

Exhibit 1

AGREEMENT

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Poniard Pharmaceuticals, Inc.

Date:	February 13, 2009
ABINGWORTH MANAGEMENT LIMITED
By:	/s/ James Abell
Name:	James Abell
Title:	Executive Director
ABINGWORTH LLP
By:	/s/ James Abell
Name:	James Abell
Title:	Member